Bristol Myers Squibb (BMS) has announced a $400-million investment at its Dublin, Ireland (Cruiserath) campus for the build and design of a sterile drug-product (SDP) manufacturing facility.  

This will be the company’s first European SDP facility for biologics and will add drug-product manufacturing capabilities to the site, which now supports biologic manufacturing operations for bulk drug substances. The facility is currently in the design phase. Construction is expected to commence in March 2024, with completion in 2026. 

The new investment will expand manufacturing and laboratory capacity at the campus. The new facility will support the manufacturing and supply of existing medicines as well as serve as a launch excellence facility for pipeline assets. 

The company anticipates that there will be a further 350 roles created in Ireland as part of this investment to bring the total number of BMS employees at the campus to more than 1,000. 

Source: IDA Ireland and Bristol Myers Squibb